A detailed history of Advisors Asset Management, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 38,576 shares of NBIX stock, worth $4.84 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
38,576
Previous 34,027 13.37%
Holding current value
$4.84 Million
Previous $4.68 Million 5.19%
% of portfolio
0.08%
Previous 0.09%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$114.58 - $153.15 $521,224 - $696,679
4,549 Added 13.37%
38,576 $4.44 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $181,371 - $198,461
1,386 Added 4.25%
34,027 $4.68 Million
Q1 2024

May 14, 2024

BUY
$130.4 - $143.74 $1.27 Million - $1.4 Million
9,708 Added 42.33%
32,641 $4.5 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $524,304 - $656,232
-4,943 Reduced 17.73%
22,933 $3.02 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $1,074 - $1,258
-12 Reduced 0.04%
27,876 $2.63 Million
Q1 2023

May 12, 2023

BUY
$94.11 - $123.02 $49,878 - $65,200
530 Added 1.94%
27,888 $2.82 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $617,908 - $735,677
5,790 Added 26.85%
27,358 $3.27 Million
Q3 2022

Nov 08, 2022

BUY
$92.03 - $107.81 $125,252 - $146,729
1,361 Added 6.74%
21,568 $2.29 Million
Q2 2022

Aug 08, 2022

BUY
$75.79 - $100.07 $361,669 - $477,534
4,772 Added 30.92%
20,207 $1.97 Million
Q1 2022

May 17, 2022

SELL
$72.45 - $94.81 $247,271 - $323,586
-3,413 Reduced 18.11%
15,435 $1.45 Million
Q4 2021

Feb 15, 2022

SELL
$79.65 - $106.22 $97,332 - $129,800
-1,222 Reduced 6.09%
18,848 $1.61 Million
Q3 2021

Nov 12, 2021

SELL
$86.18 - $99.03 $184,425 - $211,924
-2,140 Reduced 9.64%
20,070 $1.93 Million
Q2 2021

Jul 30, 2021

BUY
$89.43 - $102.27 $89,251 - $102,065
998 Added 4.7%
22,210 $2.16 Million
Q1 2021

May 07, 2021

BUY
$87.57 - $119.4 $58,496 - $79,759
668 Added 3.25%
21,212 $2.06 Million
Q4 2020

Feb 12, 2021

BUY
$86.91 - $108.33 $244,217 - $304,407
2,810 Added 15.85%
20,544 $1.97 Million
Q3 2020

Nov 16, 2020

SELL
$96.16 - $135.15 $56,734 - $79,738
-590 Reduced 3.22%
17,734 $1.71 Million
Q2 2020

Aug 12, 2020

BUY
$85.09 - $130.36 $285,136 - $436,836
3,351 Added 22.38%
18,324 $2.24 Million
Q1 2020

May 15, 2020

BUY
$75.11 - $113.76 $175,006 - $265,060
2,330 Added 18.43%
14,973 $1.3 Million
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $58,763 - $80,271
677 Added 5.66%
12,643 $1.36 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $388,589 - $470,554
4,636 Added 63.25%
11,966 $1.08 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $229,000 - $289,325
-3,170 Reduced 30.19%
7,330 $619,000
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $23,288 - $30,754
336 Added 3.31%
10,500 $925,000
Q4 2018

Jan 31, 2019

BUY
$68.32 - $124.36 $214,114 - $389,744
3,134 Added 44.58%
10,164 $726,000
Q3 2018

Nov 15, 2018

BUY
$98.88 - $125.85 $358,736 - $456,583
3,628 Added 106.64%
7,030 $864,000
Q2 2018

Aug 22, 2018

SELL
$75.3 - $105.99 $2.33 Million - $3.29 Million
-31,002 Reduced 90.11%
3,402 $334,000
Q2 2018

Aug 15, 2018

BUY
$75.3 - $105.99 $2.59 Million - $3.65 Million
34,404 New
34,404 $334,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.